{
    "organizations": [],
    "uuid": "0b21122f1ff8db01ca30cca8ead470f86fea275d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-aquinox-provides-enrollment-update/brief-aquinox-provides-enrollment-update-for-leadership-301-clinical-trial-of-rosiptor-idUSASB0C51K",
    "ord_in_thread": 0,
    "title": "BRIEF-Aquinox Provides Enrollment Update For Leadership 301 Clinical Trial Of Rosiptor",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 37 PM / Updated 9 minutes ago BRIEF-Aquinox Provides Enrollment Update For Leadership 301 Clinical Trial Of Rosiptor   Aquinox Pharmaceuticals Inc: \n* AQUINOX PROVIDES ENROLLMENT UPDATE FOR LEADERSHIP 301 CLINICAL TRIAL OF ROSIPTOR \n* AQUINOX PHARMACEUTICALS INC - ENROLLMENT TARGET REACHED IN LEADERSHIP 301 CLINICAL TRIAL OF ROSIPTOR; TOPLINE DATA ON TRACK FOR Q3 2018 ANNOUNCEMENT Source text for Eikon:  ",
    "published": "2018-02-09T15:36:00.000+02:00",
    "crawled": "2018-02-09T15:49:39.047+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "provides",
        "enrollment",
        "update",
        "leadership",
        "clinical",
        "trial",
        "rosiptor",
        "aquinox",
        "pharmaceutical",
        "inc",
        "aquinox",
        "provides",
        "enrollment",
        "update",
        "leadership",
        "clinical",
        "trial",
        "rosiptor",
        "aquinox",
        "pharmaceutical",
        "inc",
        "enrollment",
        "target",
        "reached",
        "leadership",
        "clinical",
        "trial",
        "rosiptor",
        "topline",
        "data",
        "track",
        "q3",
        "announcement",
        "source",
        "text",
        "eikon"
    ]
}